SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBUGlobeNewsWire • 3h
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBUPRNewsWire • Wednesday
Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory BoardGlobeNewsWire • 07/09/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBUGlobeNewsWire • 07/07/24
Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy PotentialSeeking Alpha • 07/03/24
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 06/02/24
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor ConferencesGlobeNewsWire • 05/30/24
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/07/24
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 04/24/24
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)GlobeNewsWire • 04/15/24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in LupusGlobeNewsWire • 04/04/24
HireRight Holdings Corp. (HRT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsBusiness Wire • 03/20/24
All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to BuyZacks Investment Research • 03/14/24
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/11/24
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024GlobeNewsWire • 01/07/24
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024GlobeNewsWire • 12/12/23
Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 12/08/23